Agreed Expert Opinion of the XI Educational International Consensus on Respiratory Medicine in Pediatrics on the organization of pertussis vaccination

Pertussis remains a relevant public health issue in the Russian Federation. The recorded high incidence rate and trends indicate wide circulation of the pertussis pathogen. There has been increased pertussis incidence in children under 14 years of age due to the lifting of restrictive measures. From January through May 2022, there is a 100% increase in the pertussis incidence compared to the same period in 2021. The optimal strategy for reducing morbidity and mortality is vaccination during the first year of life and the first booster vaccination during the second year, ensuring maximum coverage of preventive vaccinations for young children, as well as the introduction of the second revaccination of children of 6–7 years old and subsequent revaccinations of children 14 years old, adolescents and adults from 18 years old – every ten years from the last vaccination, using a combined vaccine for revaccination against pertussis (cell-free), diphtheria (with a reduced antigen content) and tetanus. During the implementation of the regional programs at stage I, it is possible to introduce additional revaccinations for children, adolescents, and adults at risk who need revaccination against pertussis, primarily with TDaP for children from 3 months to 3 years 11 months 29 days; acellular TDaP (Infanrix) for children from 2 months to 7 years of age; acellular TDaP-IPV-HBV/Hib (Infanrix Hexa) in children from 2 months to 2 years of age; acellular TDaP-IPV/Hib (Pentaxim) for children from 2 months of age; acellular TDaP (Adacel) for children 4 years of age and older following their labels.